Skip to content

Ovarian Tissue Cryopreservation for Fertility Preservation

Ovarian Tissue Cryopreservation for Fertility Preservation

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01682525
Enrollment
0
Registered
2012-09-11
Start date
2012-05-31
Completion date
2015-03-31
Last updated
2016-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Fertility preservation, Ovarian Tissue, Cryopreservation, Assisted Reproductive Technology

Brief summary

To provide a novel fertility preservation option for patients facing a fertility threatening cancer diagnosis or treatment regimen by establishing an ovarian tissue cryopreservation program. To determine if ovarian tissue cryopreservation provides women with a useful, successful option for fertility preservation The hypothesis is that ovarian tissue cryopreservation for fertility preservation provides an alternative option for fertility preservation.

Interventions

OTHERFrozen ovarian tissue

Use of ovarian tissue cryopreserved and stored at Boston IVF

Sponsors

Boston IVF
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Will undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy which are likely to result in permanent loss of subsequent ovarian function or diminished fertility * Have a medical condition or malignancy that requires removal of all or part of one or both ovaries * Patients may have newly diagnosed or recurrent disease * Be in good health so as to be able to undergo laparoscopic surgery as determined by history and physical examinations, and consultation with the medical oncologist, reproductive endocrinologist, surgeon and anesthesiologist

Exclusion criteria

* Moderate to high-risk of ovarian failure due to treatment * Documented ovarian metastasis * HIV or hepatitis (B, C)-positive serology * Absolute surgical contraindications * ECOG performance status of 0 or 1 * Pregnancy * Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent

Design outcomes

Primary

MeasureTime frameDescription
Safety10 yearsSafety, which will be assessed by tracking the number of minor and major complications of the procedure including the following: * Minor: Local infection * Major: Blood loss requiring blood transfusion, major infection requiring admission or parental antibiotics, injury to surrounding organs requiring further procedures, hospitalization due to unforeseen operative complication

Secondary

MeasureTime frameDescription
Efficacy10 years* Proportion of women who attempt pregnancy * Proportion of women who become pregnant and outcome * Proportion of women using assisted reproduction after re-implantation or ovarian tissue. * Menstrual cyclicity and ovarian reserve in those with and without re-implantation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026